Kalmadi Sujith R, Hussein Mohamad A
Cleveland Clinic Foundation, Multiple Myeloma Multidisciplinary Clinical Research Program, Taussig Cancer Center, Cleveland, Ohio 44195, USA.
Acta Haematol. 2006;116(1):1-7. doi: 10.1159/000092341.
Multiple myeloma is a clonal disorder of plasma cells which is considered incurable with currently available therapies. Substantial advances have been achieved in the past decade with the identification of cellular mechanisms that confer drug resistance. This has resulted in newer agents such as arsenic trioxide (Trisenoxt), lenalidomide (Revlimid) and bortezomib (Velcade) with promising activity in this disease. In this review article we will outline the history, mechanisms of action, pharmacology, and clinical trials of arsenic trioxide in multiple myeloma.
多发性骨髓瘤是一种浆细胞的克隆性疾病，目前可用的治疗方法认为其无法治愈。在过去十年中，随着赋予耐药性的细胞机制的发现，取得了重大进展。这导致了新型药物的出现，如三氧化二砷（Trisenoxt）、来那度胺（Revlimid）和硼替佐米（Velcade），它们在这种疾病中具有有前景的活性。在这篇综述文章中，我们将概述三氧化二砷在多发性骨髓瘤中的历史、作用机制、药理学和临床试验。
